Intercell, Novartis vaccine goes into PhII; Pfizer's Prevnar effective in adolescents;

> Intercell has started a pivotal Phase II/III efficacy study of its Pseudomonas aeruginosa vaccine candidate. The move comes after a Phase II trial showed the vaccine reduced death rates; the vaccine is part of a strategic alliance with Novartis ($NVS). Intercell release

> PX'Therapeutics is launching a Phase I clinical trial of an HIV prophylactic vaccine as part of the EU collaborative project EuroNeut-41. PX'Therapeutics release

> Patient recruitment has started for an early clinical trial for PD01, an experimental Parkinson's disease vaccine from AFFiRiS. Article

> Pfizer's ($PFE) Prevnar, currently approved for use in infants and young children, has shown efficacy in children and young people up to the age of 17. Pfizer release

> Taiwan's Adimmune is planning clinical trials for its domestic H5N1 vaccine. Article

> Flu vaccines are safe for most children with egg allergies. News

> India welcomes the Gennova Vaccine Formulation Center, a $7.9 million facility dedicated to manufacturing vaccines. Story

> Ghana has approval from the WHO to launch four meningitis vaccines. Item

And Finally… The Infectious Disease Research Institute has received a $1 million grant to develop a leprosy diagnostic and vaccine as part of an effort to eliminate the disease. IDRI release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.